Bafna Pharmaceuticals Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Bafna Pharmaceuticals Ltd. on BSE

Search Inside the pdf :

Bafna Pharmaceuticals Ltd.

08 Apr 2025

Company Update

Bafna Pharmaceuticals Ltd - 532989 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

Certificate under Regulation74(5) of SEBI (DP) Regulations, 2018 for Quarter ended March 31, 2025

pdf

Bafna Pharmaceuticals Ltd.

01 Apr 2025

Company Update

Bafna Pharmaceuticals Ltd - 532989 - Announcement under Regulation 30 (LODR)-Change in Directorate

BSE India

Intimation for resignation of Mr. Krishna Yeachuri as an Independent Director of the Company with effect from closure of business hours on March 31, 2025.

pdf

Bafna Pharmaceuticals Ltd.

01 Apr 2025

Company Update

Bafna Pharmaceuticals Ltd - 532989 - Announcement under Regulation 30 (LODR)-Resignation of Director

BSE India

We hereby inform that Mr. Krishna Yeachuri has tendered his resignation as an Independent Director of the Company with effect from close of business hours on March 31, 2025.

pdf

Bafna Pharmaceuticals Ltd.

01 Apr 2025

SAST

Bafna Pharmaceuticals Ltd - 532989 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

BSE India

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for SRJR Lifesciences LLP

pdf

Bafna Pharmaceuticals Ltd.

01 Apr 2025

SAST

Bafna Pharmaceuticals Ltd - 532989 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

BSE India

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for SRJR Lifesciences LLP

pdf

Bafna Pharmaceuticals Ltd.

31 Mar 2025

Company Update

Bafna Pharmaceuticals Ltd - 532989 - Disclosure Under Regulation 7(2) Of SEBI (PIT) Regulations, 2015

BSE India

We hereby enclose the Disclosure under Regulation 7(2)(a) of SEBI (Prohibition of Insider Trading) Regulations, 2015 received from M/s. SRJR Lifesciences LLP regarding the Sale of Shares of the Company pursuant to Offer for Sale (OFS) through Stock Exchange Mechanism. This submission is made pursuant to Regulation 7(2)(b) of SEBI (Prohibition of Insider Trading) Regulations, 2015.

pdf

Bafna Pharmaceuticals Ltd.

26 Mar 2025

Company Update

Bafna Pharmaceuticals Ltd - 532989 - Notice of Offer for Sale of Shares by Promoter & …

BSE India

Notice of the proposed offer for sale ("OFS") of equity shares of face value of Rs. 10 each fully paid-up ("Equity Shares") of Bafna Pharmaceuticals Ltd (the "Company") by its promoter, SRJR Lifesciences LLP (the "Seller"), through the stock exchange mechanism (the "Notice").

pdf

Bafna Pharmaceuticals Ltd.

26 Mar 2025

SAST

Bafna Pharmaceuticals Ltd - 532989 - Closure of Trading Window

BSE India

Intimation for Closure of Trading Window

pdf

Bafna Pharmaceuticals Ltd.

11 Feb 2025, 01:05PM

Company Update

BAFNA PHARMACEUTICALS LTD. - 532989 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

We hereby enclose the Newspaper Publication for the Unaudited Financial Results of the Company for the Quarter and Nine Months ended December 31, 2024 published in "Business Standard" and "Makkal Kural" on February 08, 2025

pdf

Bafna Pharmaceuticals Ltd.

06 Feb 2025

Corp. Note

BAFNA PHARMACEUTICALS LTD. - 532989 - Integrated Filing (Financial)

BSE India

Integrated Filing (Financial) for the Quarter and Nine Months ended December 31, 2024.

pdf

Is Bafna Pharmaceuticals Ltd. worth buying?

23 Votes:

Buy 69.57%

Sell 21.74%

Hold 8.7%